Pro Medicus Limited

The Business

Pro Medicus develops and licenses Visage, a cloud-native medical imaging platform that allows radiologists to view, manipulate, and report on diagnostic images (CT scans, MRIs, X-rays) streamed directly from the cloud rather than downloaded to local hardware. North America generates 93% of revenue, with Australia and a nascent European operation contributing the balance. The company charges per exam, meaning revenue scales with hospital imaging volumes at near-zero marginal cost. This transaction-based model, combined with multi-year contracts and deep integration into clinical workflows, produces recurring revenue with no meaningful churn: not a single client has been lost in the platform's history.

Recent Performance

Revenue grew 32% in FY25 to $213 million, accelerating from 26% in FY24, as new US hospital go-lives converted contracted wins into billable exams. EBIT margins expanded from 66% to 68%. First-half FY26 results sustained the trajectory at 28% revenue growth, with total contract value (the dollar amount of new deals signed) reaching $280 million in a single half. The stock has re-rated from around $70 eighteen months ago to $130 today, reflecting both earnings delivery and further multiple expansion.

Outlook

We forecast revenue growing from $275 million in FY26 to $423 million by FY28, a 22% compound annual growth rate. US market share gains from roughly 10% toward 20% of a $6 billion addressable market underpin this trajectory. EBIT margins should hold in the 71-73% range as the inherently scalable cloud architecture keeps costs near-flat while revenue compounds. A pathology imaging module, expected to launch in calendar 2026, could expand the addressable market by 30-50% over three to five years, though we have not included material revenue from it in our base case.

Key Risks

Revenue growth is the most sensitive lever in any assessment of Pro Medicus. The founder-CEO has led the company for 40 years with no disclosed succession plan, and an unplanned departure could trigger a meaningful de-rating of the management premium embedded in the stock. Most critically, a normalisation of the market's implied cost of equity (the return investors demand for holding the stock) from roughly 7% toward the 11-12% range that standard models suggest would destroy a substantial portion of market value with zero change in business fundamentals.

What to Watch

The thesis-defining event is the FY26 full-year result in August 2026, which will confirm whether second-half revenue growth sustained above 25% and whether total contract value remained above $200 million per half, the minimum pace needed to support the growth trajectory.

• CY2026 Pathology module launch — successful commercialisation would validate TAM expansion and represents the single largest upside catalyst.
• 1-3 years European contract pipeline — scaling beyond the Heidelberg University Hospital beachhead would reduce geographic concentration risk and open a large new market.

Company Description

Pro Medicus is a Melbourne-headquartered medical imaging software company that has evolved from a local radiology IT provider into the dominant cloud-native platform in the US enterprise imaging market. Its core product, Visage, is a picture archiving and communication system (PACS), the software hospitals use to store, retrieve, and display medical images for diagnostic interpretation. Unlike legacy systems from GE HealthCare or Philips that require on-premise hardware, Visage streams images directly from the cloud, eliminating local storage and enabling radiologists to access studies from any location with near-instant load times.

North America accounts for 93% of revenue, primarily through multi-year contracts with large US health systems. Australia contributes roughly 5% as a mature legacy market. Europe, anchored by a contract with Heidelberg University Hospital in Germany, represents approximately 2% but is the fastest-growing segment from a low base. The company employs around 200 people, a remarkably lean headcount for a business generating over $200 million in annual revenue.

Where the Growth Is

US market share gains are the primary engine. Pro Medicus holds roughly 10% of the $6 billion US enterprise imaging market and is gaining approximately 2 percentage points per year as hospitals migrate from legacy on-premise systems to cloud-native alternatives. At the current pace, US share could reach 20% within five years, adding $150 to $200 million in incremental revenue. This growth is structural rather than cyclical: 70% of US hospitals have not yet migrated to cloud imaging, and the shift is accelerating as radiologist shortages make efficiency tools non-discretionary. The $1 billion-plus in contracted total contract value provides multi-year visibility into this pipeline.

Competitive Position

Pro Medicus possesses a wide competitive moat that is actively widening. Three reinforcing advantages create this position. First, the cloud-native architecture was purpose-built over 15 years, a development timeline that no competitor has replicated. Legacy vendors like GE HealthCare and Philips would need to re-architect their entire platform rather than bolt cloud features onto existing systems. Second, switching costs are extreme: Visage integrates deeply into clinical workflows, electronic health records, and AI tools, making replacement a multi-year, multi-million-dollar undertaking. The 100% client retention rate across the platform's entire history evidences this lock-in. Third, the per-exam pricing model aligns Pro Medicus's revenue with hospital volumes, creating a shared incentive structure that legacy per-site licensing does not match.

Sectra, the Swedish medical imaging company, is the closest competitor. GE HealthCare and Philips compete on installed base but are losing share. No pure cloud-native competitor of comparable scale exists. Competitive replication would take a decade given the regulatory approvals, clinical validation, and health system trust required.

Management & Capital Discipline

Founder-CEO Sam Hupert has led Pro Medicus for over 40 years and holds approximately 13% of the company. His track record of under-promising and over-delivering is among the strongest on the ASX. Capital allocation has been conservative and shareholder-aligned: zero debt throughout the growth phase, a 50% payout ratio with fully franked dividends, and $222 million in cash on the balance sheet. The company has avoided dilutive acquisitions entirely, preferring organic development of new modules (cardiology, pathology) over buying growth.

The honest observation most analysts avoid: the complete absence of any succession disclosure for a sole-founder business with a CEO in his seventies is a governance gap. Hupert's personal credibility is deeply embedded in the company's market premium. The board has not publicly addressed what happens when he steps back.

Financial Position

The balance sheet is a fortress. Zero debt, $222 million in cash, and free cash flow conversion above 90% of net profit mean the company could fund operations for years without external capital even if revenue flatlined. Working capital is actually negative (the company collects cash before incurring costs), so growth is self-funding. Capital expenditure runs below 2% of revenue, reflecting the asset-light nature of a pure software business.